Schedule 13G ownership disclosure

Compass Therapeutics Inc

Security class unavailable · CUSIP: 20454B104

Event date: 2024-09-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,843,286
Percent of class
1.3000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001274173-24-000086
Form type
SC 13G/A
Filer
Compass Therapeutics, Inc.
CIK
CIK 1738021
Filed
Nov 14, 2024
Reporting period
Sep 30, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub